# Switchpoint Bio raises €4.75 million for blood-based drug response platform

_Published Wednesday, November 11, 2026 at 6:00 AM EST · Capital · Latest · Tier 2 — Notable_

![Switchpoint Bio raises €4.75 million for blood-based drug response platform — Primary](https://www.eu-startups.com/wp-content/uploads/2026/11/Screenshot-2026-11-11-at-1.41.17-PM-1024x739.png)

Switchpoint Bio has raised €4.75 million ($5.3 million) in pre-Seed financing to develop its blood-based platform for studying disease and treatment response, EU-Startups reports. Treehouse Delmar Investments supplied €4.48 million ($5 million) of the round.

The company says it combines AI with targeted profiling of DNA methylation, chemical marks on DNA, to track biological changes in circulating immune cells. It is moving into clinical and industry validation, including testing in systemic lupus erythematosus to assess whether blood samples can reveal disease-related immune states over treatment.

The financing will support validation, larger clinical and biobank datasets, platform development and scientific and technical hiring in Helsinki and Cambridge, Massachusetts.

## Sources

- [EU-Startups](https://www.eu-startups.com/2026/11/fresh-out-of-stealth-switchpoint-bio-raises-e4-75-million-to-decode-disease-and-drug-response-through-blood-tests/)

---
Canonical: https://techandbusiness.org/newswire/txEZGf6noj2TDN39hRbG4v
Published: 2026-11-11T11:00:09.541Z
Story chronology: 2026-11-11T08:14:31.000Z
Retrieved: 2026-11-11T12:44:33.744Z
Publisher: Tech & Business (techandbusiness.org)